<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03114631</url>
  </required_header>
  <id_info>
    <org_study_id>RRPCEM_DC1</org_study_id>
    <nct_id>NCT03114631</nct_id>
  </id_info>
  <brief_title>Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer</brief_title>
  <official_title>Single-center Trial Evaluating the Safety and Efficacy of MUC-1/WT-1 Peptide or Tumor Lysate-pulsed Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Republican Research and Practical Center for Epidemiology and Microbiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Belarusian state medical university</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Republican Research and Practical Center for Epidemiology and Microbiology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial evaluates the safety and efficacy of MUC-1/WT-1 peptide and/or tumor lysate-pulsed
      dendritic cell Immunotherapy for the patients with pancreatic cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial evaluates the safety and efficacy of dendritic cell Immunotherapy for the patients
      with pancreatic cancer. Dendritic cells are obtained from blood monocytes using standard
      protocol.

      Two options for dendritic cell priming are used: MUC-1/WT-1 peptides for the patients with
      unresectable tumor and/or tumor lysates for the patients undergoing tumor resection.

      The dendritic cells are them matured and injected subcutaneous (all patients) and
      intratumorally (when possible).
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 9, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with PR or CR at 1 year</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Survived at 1 Year</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antigen-specific immune response</measure>
    <time_frame>1 year</time_frame>
    <description>The increase of antigen-specific T-cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating tumor cells count</measure>
    <time_frame>1 year</time_frame>
    <description>Decrease of EpCAM+CD45- circulating tumor cells count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response</measure>
    <time_frame>1 year</time_frame>
    <description>Decrease of T-regulatory cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Survived at 2 Years</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Survived at 3 Years or more</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Dendritic Cells</condition>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Dendritic cells lysate-pulsed group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated according to clinical protocols plus autologous dendritic cells, pulsed with tumor lysate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients treated according to clinical protocols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dendritic cells peptide-pulsed group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated according to clinical protocols plus autologous dendritic cells, pulsed with MUC-1/WT-1 peptides</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dendritic cells pulsed with tumor lysate</intervention_name>
    <arm_group_label>Dendritic cells lysate-pulsed group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dendritic cells pulsed with MUC-1/WT-1 peptides</intervention_name>
    <arm_group_label>Dendritic cells peptide-pulsed group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically or cytologically confirmed pancreatic cancer (adenocarcinoma);

          -  HLA-A2 expression by tumor cells;

          -  WT-1/MUC-1 expression by tumor cells.

        Exclusion Criteria:

          -  refuse of patient to participate in the trial;

          -  pregnancy/lactation;

          -  intercurrent severe chronic diseases;

          -  HIV, Hepatites B/C;

          -  active tuberculosis;

          -  alcohol use disorder/drug addiction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander V. Prokharau, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Belarussian State Medical University, Minsk, Belarus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrei Y Hancharou, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>The Republican Research and Practical Center for Epidemiology and Microbiology, Minsk, Belarus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Minsk City Clinical Oncologic Dispensary</name>
      <address>
        <city>Minsk</city>
        <zip>220000</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
  </location_countries>
  <link>
    <url>http://immunologist.su/articles/pancrcancer.pdf</url>
    <description>previous results</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2017</study_first_submitted>
  <study_first_submitted_qc>April 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>April 13, 2017</last_update_submitted>
  <last_update_submitted_qc>April 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Republican Research and Practical Center for Epidemiology and Microbiology</investigator_affiliation>
    <investigator_full_name>Andrei Y. Hancharou</investigator_full_name>
    <investigator_title>Head of the Laboratory for Immunology and Cellular Biotechnology</investigator_title>
  </responsible_party>
  <keyword>dendritic cells, pancreatic cancer, immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>http://immunologist.su/files/informed_consent.pdf</doc_url>
      <doc_comment>In Russian</doc_comment>
    </study_doc>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://immunologist.su/files/study_protocol.pdf</doc_url>
      <doc_comment>In Russian</doc_comment>
    </study_doc>
    <study_doc>
      <doc_type>Ethical Committee approval</doc_type>
      <doc_url>http://immunologist.su/files/committee_approval.pdf</doc_url>
      <doc_comment>In Russian</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

